There has been little research on the long-term usage of mitomycin C (MC) for recurrent esophageal stenoses. The study looked at the long-term effectiveness and safety of using MC locally to treat recurrent esophageal stenoses in children. This was a retrospective analysis of 39 individuals, the median age at the time of MC application being 19.5 months. Esophageal atresia, caustic ingestion, congenital esophageal stenosis, and other reasons were the etiologies of stenosis. In 35 cases, the stenosis was solitary, whereas, in four, it was numerous. Prior to MC, patients had many recurrent dilations during a 7-month period. Treatment success was established as a decrease in the number of dilations from before to after the administration of MC. The use of MC was deemed successful in 26 individuals, with 102 versus 17 dilatations. During the follow-up period following MC application, sixteen patients never required further dilatation. There were no complications associated with MC. Biopsies at the site of MC application were done in 16 participants at the end of the study and found no abnormalities. Single stenosis, short stenosis, and esophageal atresia type III were shown to be linked with MC success. It indicated that topical MC administration is an effective and safe therapy for recurrent esophageal stenosis in children.